Revised MRPs of 1,364 Anti-Cancer Formulations Come into Effect
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has implemented price controls on anti-cancer medications effective from 9th November 2026. The authority capped trade margins on the Maximum Retail Price (MRP) of 137 anti-cancer drugs based on recommendations from an Expert Committee constituted by the Directorate General of Health Services (DGHS), Ministry of Health & Family Welfare, on 17th October 2026.
As of 8th November 2026, 85 pharmaceutical companies have reported revised MRPs for 1,364 anti-cancer formulations covering 121 drugs. Significant price reductions have been achieved, with 679 brands reporting price reductions of more than 50% and the highest reported reduction reaching 96.45%. The estimated annual savings to consumers from these price reductions is projected to be ₹3,540.38 crore.
Compliance and Consumer Protection Mechanisms
Consumers can verify the revised MRP printed on medicine packs and check prices through the Pharma Sahi Daam mobile application or the NPPA website (nppa.gov.in). The regulation explicitly prohibits chemists or hospital pharmacies from charging more than the revised MRP. For pricing-related complaints or overcharging instances, consumers can register grievances through the Pharma Jan Samadhan portal or contact the NPPA helpline at 1800-111-255.